MedTrace Logo

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

NCT00673842 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2025-05-30

No results posted yet for this study

Summary

This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.

Conditions

Interventions

DEVICE

Implantable Cardioverter Defibrillator + Usual Care

Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD)

OTHER

Usual care

Usual post-MI care

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Alberta Innovation and Science

    collaborator OTHER

  • Medtronic

    collaborator INDUSTRY

  • GE Healthcare

    collaborator INDUSTRY

  • Cardiac Arrhythmia Network of Canada

    collaborator OTHER

  • Accelerating Clinical Trials Consortium

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Derek V Exner, MD, MPH · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-18
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • United States
  • Belgium
  • Canada
  • Finland
  • France
  • Germany
  • Hungary
  • Italy
  • Norway
  • Saudi Arabia
  • Slovakia
  • South Africa
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00673842 on ClinicalTrials.gov